Skilled panel says new $56Okay Alzheimer’s drug is unproven—and price $8,400 max
Enlarge / The outside of the headquarters of biotechnology firm Biogen in Cambridge, Massachusetts. (credit score: Getty | Boston Globe) Biogen’s new Alzheimer’s drug Aduhelm continues to face opposition after its contentious approval by the Meals and Drug Administration final